Antibody–drug conjugates to treat gastric cancer

Introduction Despite new treatment options, the long-term prognosis of recurrent or inoperable gastric cancer remains poor. Antibody–drug conjugates (ADCs) are a new class of drugs and have shown promising results in clinical trials.Areas covered This review focuses on recent clinical findings and development of ADCs for gastric cancer, and summarizes the relevant resistance mechanisms or future directions of ADCs.Expert opinion Novel HER2-ADCs...